Surgical wound separation
Also known as: Wound dehiscence
Methodology & AI Transparency ⓘ
Surgical wound separation Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Surgical wound separation (also termed Wound dehiscence)—coded clinically as T81.30XA across Preventive & Labs guidelines—combines evidence-based risk stratification in Surgical wound separation (T81.30XA: pairing lifestyle nutrition/exercise) with structured follow-up of ApoB, HbA1c & in Surgical wound separation (T81.30XA: hs-CRP Triad) (ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (T81.30XA)).
- 2 Real-world patient consensus: Clinical coding for Surgical wound separation uses ICD-10 T81.30XA across Preventive & Labs specialty care.
- 3 Typical cash cost range: Workup highlights for Surgical wound separation (T81.30XA): evidence-based risk stratification in Surgical wound separation (T81.30XA: pairing lifestyle nutrition/exercise).
- 4 Top reported side effects / signs: Follow-up benchmark in Surgical wound separation: maintaining 25-Hydroxy Vitamin D, in Surgical wound separation (T81.30XA: Ferritin & B12) within 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (T81.30XA).
Ask our AI Specialists anything about Surgical wound separation
What Is Surgical wound separation?
Surgical wound separation (also termed Wound dehiscence)—coded clinically as T81.30XA across Preventive & Labs guidelines—combines evidence-based risk stratification in Surgical wound separation (T81.30XA: pairing lifestyle nutrition/exercise) with structured follow-up of ApoB, HbA1c & in Surgical wound separation (T81.30XA: hs-CRP Triad) (ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (T81.30XA)).
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Surgical wound separation (code T81.30XA) is preventive medical correction in Surgical wound separation (T81.30XA: during the reversible), which Preventive Screening & Blood Biomarkers clinicians address while surveilling 25-Hydroxy Vitamin D, in Surgical wound separation (T81.30XA: Ferritin & B12) (25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (T81.30XA)).
Common Symptoms & Clinical Signs
- • Presentation of Surgical wound separation (T81.30XA): age- or family-history-guided in Surgical wound separation (T81.30XA: cancer, vascular, bone,)
- • Secondary Surgical wound separation clinical sign: proactive annual or in Surgical wound separation (T81.30XA: semiannual health checkup)
- • Symptom flares in Surgical wound separation correlating with 25-Hydroxy Vitamin D, in Surgical wound separation (T81.30XA: Ferritin & B12) deviation outside 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (T81.30XA)
- • Functional preventive & labs impact requiring evidence-based risk stratification in Surgical wound separation (T81.30XA: pairing lifestyle nutrition/exercise) evaluation (T81.30XA)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Surgical wound separation Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | T81.30XA | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Surgical wound separation (T81.30XA: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (T81.30XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Surgical wound separation (T81.30XA: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (T81.30XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, CMP & in Surgical wound separation (T81.30XA: eGFR Baseline) | Within optimal preventive reference intervals (T81.30XA) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Surgical wound separation
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Ketamine Hydrochloride Ketalar • RxCUI 206967 | General Anesthetic | 91% | $0.6682 | $ 35.56 /mo |
| Bss Plus (Balanced Salt Solution Enriched with Bicarbonate, Dextrose, and Glutathione) Bss Plus • RxCUI RXN-B00650800 | FDA Prescription Therapeutic Agent | 87% | $2.8500 | $ 213.70 /mo |
| Balanced Salt Solution Enriched with Bicarbonate, Dextrose, and Glutathione Bss Plus • RxCUI RXN-00650800-1796 | FDA Prescription Therapeutic Agent | 91% | $1.1100 | $ 53.46 /mo |
| Purell Antimicrobial Foam (Chlorhexidine Gluconate 2% Solution) Purell Antimicrobial Foam • RxCUI 1245230 | Decreased Cell Wall Integrity | 84% | $0.0074 | $ 9.03 /mo |
| Chlorhexidine Gluconate Surgical Combo Kit Dermacinrx Surgical Combopak • RxCUI 211365 | FDA Prescription Therapeutic Agent | 74% | $0.0074 | $ 8.80 /mo |
| Provon Antimicrobial Foam Handwash (Chlorhexidine Gluconate 2%) Provon Antimicrobial Foam Handwash • RxCUI 1245230-B21749850 | Decreased Cell Wall Integrity | 80% | $0.0074 | $ 9.03 /mo |
| Dermacinrx Surgical Combopak (Chlorhexidine Gluconate Surgical Combo Kit) Dermacinrx Surgical Combopak • RxCUI 259090 | FDA Prescription Therapeutic Agent | 79% | $0.0074 | $ 9.03 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Surgical wound separation)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Six Decades of Pelvic Exenterative Surgery for Gynaecological: What a 13,434-Participant Study Found PE carries substantial morbidity, while perioperative mortality was approximately 5% overall and 3.7% in post-2005 studies. In vivo (Athens, Greece) • 2026-01-15 • Meta-Analysis | N = 13,434 | 94/100 | PMID 42957251 ↗ |
| What the Latest Evidence Really Says About Efficacy of non-surgical treatments for androgenetic hair High-quality randomized controlled trials and head-to-head trials are required to support these findings and aid in the development of more standardized protocols, particularly for PRP. Journal of the European Academy of Dermatology and Venereology : JEADV • 2018-12-15 • Meta-Analysis | N = 45 | 92/100 | PMID 29797431 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefit of a flash dose of corticosteroids in digestive surgical oncology: a If significant, it might be a strong improvement on oncological outcomes for patients undergoing surgery for digestive cancers. BMC cancer • 2022-08-23 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35999521 ↗ |
| Can This Approach Help? Inside the Latest Research on Condoliase on Health-related Quality of Life in Participants With Radicular Leg Previous findings confirmed the efficacy and tolerability of condoliase for LDH management. Spine • 2025-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40066868 ↗ |
| New Insights on Effectiveness of postoperative oral administration of cephalexin and: What a 210-Participant Study Found Post-operative administration of cephalexin and metronidazole for 48-h post-cesarean delivery among obese women, in addition to the standard pre-operative prophylaxis, reduced the overall rate of surgical site infection and... Antimicrobial resistance and infection control • 2022-12-05 • Phase III Randomized Trial | N = 210 | 88/100 | PMID 36471429 ↗ |
Surgical wound separation Patient Community & “People Like Me” Threads
Filter Surgical wound separation community threads and patient logs by age, biological sex, dosage, and treatment duration.